Commission Implementing Regulation (EU) 2021/2068 [Commission Implementing Regulation (EU) 2021/2068 of 25 November 2021 amending Implementing Regulation (EU) No 540/2011 as regards the extension of the approval periods of the active substances benfluralin, dimoxystrobin, fluazinam, flutolanil, mecoprop-P, mepiquat, metiram, oxamyl and pyraclostrobin (OJ L 421, 26.11.2021, p. 25).] extended the approval period of the active substances mecoprop-P, metiram and pyraclostrobin until 31 January 2023 and of the active substances fluazinam, flutolanil and mepiquat until 28 February 2023. Commission Implementing Regulation (EU) 2018/670 [Commission Implementing Regulation (EU) 2018/670 of 30 April 2018 amending Implementing Regulation (EU) No 540/2011 as regards the extension of the approval periods of the active substances bromuconazole, buprofezin, haloxyfop-P and napropamide (OJ L 113, 3.5.2018, p. 1).] extended the approval period of the active substance buprofezin until 31 January 2023. Commission Implementing Regulation (EU) 2017/1527 [Commission Implementing Regulation (EU) 2017/1527 of 6 September 2017 amending Implementing Regulation (EU) No 540/2011 as regards the extension of the approval periods of the active substances cyflufenamid, fluopicolide, heptamaloxyloglucan and malathion (OJ L 231, 7.9.2017, p. 3).] extended the approval period of the active substance cyflufenamid until 31 March 2023.
Recital 2, Regulation (EU) 2023/114
In forcesince 16 Jan 2023